Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 August 1997Website:
http://www.arcabio.comNext earnings report:
19 July 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 19:54:44 GMTDividend
Analysts recommendations
Institutional Ownership
ABIO Latest News
MILWAUKEE , June 4, 2024 /PRNewswire/ -- Ademi LLP is investigating ARCA (NASDAQ: ABIO) for possible breaches of fiduciary duty and other violations of law in its transaction with Oruka. Click here to learn how to join the https://www.ademilaw.com/case/arca-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.
Yesterday, the previously overlooked meme stocks from 2021 began gaining significant traction. However, unlike in 2021, it was clear why GameStop's sudden surge occurred.
Clinical-stage biopharmaceutical firm ARCA Biopharma (NASDAQ: ABIO ) — which develops and commercializes cardiovascular disease therapies — saw its shares skyrocket during the midweek session. Earlier this morning, management announced a merger with Oruka Therapeutics, which ultimately aims to address chronic skin diseases.
Arca Biopharma Inc (NASDAQ: ABIO) more than doubled on Wednesday after announcing a merger agreement with Oruka Therapeutics. Oruka CEO comments on Arca Biopharma stock deal The combined company following completion of the all-stock transaction will operate as Oruka Therapeutics and trade under “ORKA” on Nasdaq.
What type of business is ARCA biopharma?
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
What sector is ARCA biopharma in?
ARCA biopharma is in the Healthcare sector
What industry is ARCA biopharma in?
ARCA biopharma is in the Biotechnology industry
What country is ARCA biopharma from?
ARCA biopharma is headquartered in United States
When did ARCA biopharma go public?
ARCA biopharma initial public offering (IPO) was on 08 August 1997
What is ARCA biopharma website?
https://www.arcabio.com
Is ARCA biopharma in the S&P 500?
No, ARCA biopharma is not included in the S&P 500 index
Is ARCA biopharma in the NASDAQ 100?
No, ARCA biopharma is not included in the NASDAQ 100 index
Is ARCA biopharma in the Dow Jones?
No, ARCA biopharma is not included in the Dow Jones index
When does ARCA biopharma report earnings?
The next expected earnings date for ARCA biopharma is 19 July 2024